首页> 外国专利> METHOD TO IDENTIFY SUBJECTS AT HIGHER RISK TO DEVELOP AN AUTOIMMUNE DISEASE BASED ON GENETIC AND/OR PHENOTYPIC SCREENING FOR EPISTATIC VARIANTS IN DDX39B (RS2523506) AND IL7R (RS6897932)

METHOD TO IDENTIFY SUBJECTS AT HIGHER RISK TO DEVELOP AN AUTOIMMUNE DISEASE BASED ON GENETIC AND/OR PHENOTYPIC SCREENING FOR EPISTATIC VARIANTS IN DDX39B (RS2523506) AND IL7R (RS6897932)

机译:在DDX39B(RS2523506)和IL7R(RS6897932)中,基于遗传和/或表型筛选在遗传和/或表型筛查的情况下识别受试者的受试者以产生自身免疫性疾病(RS6897932)

摘要

The present invention includes a method, kits, and assays for identifying a human subject as having an increased risk of developing an autoimmune disease, or a human subject with multiple sclerosis caused by elevated soluble Interleukin 7 receptor (sIL7R), by obtaining a biological sample and detecting or measuring in the biological sample an amount of a soluble Interleukin-7 receptor (sIL7R) and an amount of an RNA Helicase DDX39B, whereby a lower expression of DDX39B and a higher secretion of sIL7R identifies the subject from which the biological sample was obtained as having an increased risk of developing an autoimmune disease, when compared to a human subject not having an autoimmune disease. The present invention also includes a method of modifying a treating of subjects based on the lower expression of RNA Helicase DDX39B alone or in combination with an increase in sIL7R.
机译:本发明包括用于鉴定人受试者的方法,试剂盒和测定,其具有增加自身免疫疾病的风险,或者通过获得生物样品,通过升高的可溶性白细胞介素7受体(SIL7R)引起的多发性硬化的人体受试者在生物样品中检测或测量的可溶性白细胞介素-7受体(SIL7R)的量和RNA HelicaseDDX39B的量,由此DDX39B的较低表达和SIL7R的更高分泌鉴定了生物样品的受试者与没有自身免疫疾病的人类的受试者相比,获得了发展自身免疫疾病的风险增加。本发明还包括根据RNA HelicaseDDX39B单独或与Sil7R的增加组合改性受试者治疗受试者的方法。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号